The Optilume device includes a balloon coated with paclitaxel. The Food and Drug Administration (FDA) has approved the Optilume ® Urethral Drug Coated Balloon (DCB) to treat patients with obstructive ...
The FDA has granted approval to Urotronic Inc. for its Optilume urethral drug-coated balloon (DCB) for the treatment of male urethral strictures. The device inhibits new scar tissue growth that may ...
Synchronous metastatic disease is characterized by the presence of metastatic lesions, in addition to the primary tumor, at diagnosis. Investigators in South Korea demonstrated the benefit in a ...
The committee noted that the clinical evidence showed Optilume to be effective in improving clinically relevant outcomes including anatomical success, peak flow rate and international prostate symptom ...
For permission requests, please contact NEJM Reprints at [email protected] ...
Read before the New England Branch of the American Urological Association, April 25, 1931. Riley — Assistant Professor of Genito-Urinary Surgery, Harvard Medical School. For record and address of ...
PORTSMOUTH, N.H., July 10, 2025 /PRNewswire/ -- Effective July 1, 2025, Blue Cross Blue Shield of Michigan (BCBSM) has issued a new medical policy under CPT code 52284, extending coverage for Laborie ...
The FDA has granted approval to Urotronic Inc. for its Optilume urethral drug-coated balloon (DCB) for the treatment of male urethral strictures. The device inhibits new scar tissue growth that may ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback